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Abstract Mdm2 is a RING ¢nger E3 ubiquitin ligase, which
promotes ubiquitination and proteasomal degradation of the p53
tumor suppressor protein. Acetylation of p53 regulates p53’s
transcriptional activity and inhibits Mdm2-mediated p53 ubiq-
uitination and degradation. We now report that Mdm2 is also a
target for acetylation. Mdm2 is acetylated in vitro by CREB-
binding protein (CBP) and to a lesser extent by p300, but not by
p300/CPB-associated factor. Acetylation occurs primarily with-
in the RING ¢nger domain of Mdm2. In vivo acetylation of
Mdm2 was detected easily with CBP but not p300. E⁄cient
in vivo acetylation required the preservation of the RING ¢nger.
An Mdm2 mutant (K466/467Q) mimicking acetylation is im-
paired in its ability to promote p53 ubiquitination, as well as
Mdm2 autoubiquitination. Moreover, K466/467Q is defective in
promoting p53 degradation in living cells. We thus suggest that
acetyltransferases may modulate cellular p53 activity not only
by modifying p53, but also by inactivating Mdm2.
6 2004 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
Histone acetyltransferases (HATs) such as p300, CREB-
binding protein (CBP) or p300/CPB-associated factor (P/
CAF) act as coactivators for sequence-speci¢c transcription
factors. HAT-mediated facilitation of gene expression usually
involves acetylation by HATs of core histones at the target
promoters, generating a more accessible chromatin structure
for transcription factors [1,2]. Acetylation can also occur on
the transcription factors themselves [3]. The tumor suppressor
p53 was the ¢rst transcription factor shown to be acetylated
[4]. This stimulated a search for additional non-histone targets
of HATs, as a result of which many novel HAT target pro-
teins involved in di¡erent aspects of cellular regulation have
been identi¢ed [3].
p53 occupies a central position in an intricate stress signal-
ing network [5^9]. Various types of oncogenic stress provoke
a cellular p53 response manifested, in most cases, by stabili-
zation of this short-lived protein. Once activated, p53 trans-
activates or transrepresses di¡erent sets of target genes, lead-
ing to a series of cellular consequences including growth arrest
at G1 and G2, apoptosis, senescence, di¡erentiation and
DNA repair. Because p53 is a potent inhibitor of cell growth
as well as a potent inducer of cell death, its cellular activity
must be held in tight control. A major role in the control of
p53 activity has been assigned to the Mdm2 oncoprotein.
Mdm2 participates in a negative autoregulatory feedback
loop with p53, which works as a sensitive switch to turn
p53 on or o¡ [5,10,11]. To a large extent, Mdm2 exerts its
inhibitory e¡ect on p53 through controlling p53 protein levels
[12,13], acting as an E3 ubiquitin ligase to promote p53 ubiq-
uitination and proteasomal degradation [14,15]. The E3 func-
tion of Mdm2 requires its RING domain, located at the
CP-terminal part of the protein. In addition, Mdm2 can inhibit
p53’s transcriptional activity by a direct interaction that oc-
cludes the p53 transactivation domain [11,16].
Recent studies suggest the existence of a complex interplay
between Mdm2 and acetyltransferases. Mdm2 can associate
with the C/H1 region of p300 and the N-terminal region of
CBP [17,18]. On the one hand, this interaction can enhance
the ability of Mdm2 to promote p53 polyubiquitination and
degradation [17,19]. On the other hand, CBP binding to
Mdm2 was proposed to reduce the availability of CBP for
p53 interaction, resulting in reduced transcriptional activity
of p53 [18]. Furthermore, Mdm2 has been shown to reduce
HAT-mediated p53 acetylation, either by directly interfering
with the HAT activity of these proteins or through its recruit-
ment of the histone deacetylase HDAC1 [20^22]. In an e¡ort
to gain more insight into the functional interaction between
p300/CBP and Mdm2, we explored the idea that Mdm2 may
not only modulate p53 acetylation, but also be itself a direct
substrate for regulatory acetylation by HATs. We report that
Mdm2 can be acetylated in vitro by CBP and, to a lesser
extent, by p300; furthermore, Mdm2 is acetylated within liv-
ing cells, and this is enhanced by CBP. An Mdm2 mutant,
mimicking the acetylated state, exhibits impaired E3 ligase
activity and is de¢cient in promoting p53 degradation. Thus,
HAT-mediated acetylation may impinge on the p53 pathway
not only through modi¢cation of p53, but also through inac-
tivation of Mdm2.
2. Materials and methods
2.1. Cells and transfections
H1299 cells (ATCC) were maintained at 37‡C in RPMI medium
(Sigma) supplemented with 10% fetal calf serum (FCS, Sigma). p53/
mdm2 double null mouse embryonic ¢broblasts (MEFs) (clone 174-2,
kindly provided by G. Lozano) and HEK-293 cells were maintained
at 37‡C in Dulbecco’s modi¢ed Eagle’s medium (DMEM) supple-
mented with 10% heat-inactivated fetal bovine serum (FBS, Sigma)
and antibiotics. MEFs were maintained in DMEM supplemented with
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10% heat-inactivated FBS, non-essential amino acids and L-mercap-
toethanol (at 0.4 Wl/100 ml). H1299 cells and HEK-293 cells were
transfected with the aid of either calcium phosphate or the JetPEI
reagent (PolyPlus Transfection).
2.2. Immunoblotting analysis
Steady-state protein levels were monitored as described [12]. Cells
were washed with ice-cold phosphate-bu¡ered saline (PBS) and lysed
in RIPA bu¡er. Following three rounds of vigorous vortexing at 5 min
intervals, lysates were cleared by centrifugation at 4‡C for 10 min.
Aliquots containing 20 Wg total protein (Bio-Rad protein assay) were
resolved on 10% sodium dodecyl sulfate (SDS)^polyacrylamide gels
and transferred to nitrocellulose membranes (BA83, Schleicherp
Schuell). Samples for p53 ubiquitination assays were run on 8%
SDS^polyacrylamide gel electrophoresis (PAGE) gels. Membranes
were probed with the indicated antibodies and developed with the
enhanced chemiluminescence (ECL) kit (Amersham).
2.3. PreScission protease and protein puri¢cation
Glutathione-S-transferase (GST)-Mdm2 or GST-Mdm2/4KR solu-
tions, eluted from glutathione beads, were dialyzed against 20 mM
Tris^Cl pH 7.5, 1 mM dithiothreitol (DTT), 10% glycerol overnight at
4‡C. 1.5 mg of GST fusion protein was cleaved in 1 ml of bu¡er
containing 150 mM, 0.01% Triton X-100, 1 mM DTT, and 40 units
PreScission protease (Amersham), incubated at 4‡C for 5 h. To re-
move the released GST from the solution, 1 ml glutathione agarose
beads were washed twice with 10 ml of cell lysis bu¡er (20 mM Tris
pH 8.0, 120 mM NaCl, 1 mM ethylenediamine tetraacetic acid
(EDTA), 0.5% NP40 10 WM trichostatin A (TSA) and Sigma protease
inhibitor cocktail diluted 1:200), coated for 2 h at 4‡C by gentle
agitation with 10 ml of 3% bovine serum albumin (BSA) (FV) in
cell lysis bu¡er containing 10% glycerol, 1 mM DTT, and ¢nally
washed again three times with lysis bu¡er. Coated beads were incu-
bated with the cleavage products at 4‡C for 2 h, followed by centri-
fugation and collection of GST-free protein in the supernatant. Ali-
quots were stored at 380‡C.
2.4. In vitro acetylation
In vitro acetylation was performed as described [4]. Recombinant
CBP/cf was generated by fusing a CBP catalytic fragment (residues
1196^1718) to GST [23]. A catalytically inactive derivative was made
by introducing Leu1690Lys and Cys1691Leu mutations into CBP/cf.
For in vitro acetylation assays using anti-p300 or anti-CBP immuno-
precipitates, cells from three 15-cm dishes of the p53/mdm2 double
null MEFs at 85% con£uence, or 10 10-cm dishes of HEK-293 cells
transfected with 15 Wg/dish of p300-HA or CBP-HA expression plas-
mid DNA, were lysed by incubation on ice for 20 min in 1.5 ml of
lysis bu¡er, followed by three rounds of freeze-thawing. The cleared
supernatant was taken for immunoprecipitation with protein A Se-
pharose 4B fast £ow beads (Sigma) at 4‡C for 1 h, using anti-CBP
(Santa Cruz, monoclonal C1) or a monoclonal anti-HA (HA.11, Bab-
co) antibody for MEFs or transfected HEK-293 cells, respectively.
The beads were washed three times with lysis bu¡er+1 mM DTT,
then divided into aliquots and stored at 380‡C. Loaded beads were
employed in in vitro acetylation assays, in combination with 2 Wg of
puri¢ed bacterially expressed GST-Mdm2, from which the GST por-
tion had been cleaved o¡ with PreScission protease (Amersham), in a
total reaction volume of 30 Wl. Reaction products were resolved by
SDS^PAGE. Gels were stained with Coomassie brilliant blue,
scanned, and then treated with Amplify (NAMP100, Amersham) at
room temperature for 30 min, dried and exposed to Kodak BioMAX-
MS ¢lm.
2.5. In vivo acetylation
In vivo acetylation assays were performed as described [4]. Trans-
fected HEK-293 cells (2U106/10 cm dish, a total of 10 dishes) were
treated with MG132 (25 WM) for 4 h, and resuspended in 2-ml micro-
centrifuge tubes in 1.5 ml of labeling medium containing 2 mCi/ml
[3H]acetate, 25 WM MG132, 5 WM TSA, 5 mM nicotinamide and 50
Wg/ml cycloheximide, in fully complemented DMEM. The tubes were
rotated at 37‡C for 45 min (without cycloheximide) or 90 min (with
cycloheximide). Following washing with 1 ml cold PBS, cells were
lysed in 400 Wl of 1% SDS^triethanolamine-bu¡ered saline (TBS) by
boiling twice for 5 min after vigorous vortexing. 800 Wl of TBS con-
taining 1.5% Triton X-100, 5 WM TSA and 5 mM nicotinamide was
added to each tube, and the supernatant was collected after centrifu-
gation at 15 000 rpm for 15 min at room temperature. Immunopre-
cipitation of HA-Mdm2 from HEK-293 cell extracts was performed
with a monoclonal anti-HA antibody (HA.11, Babco). Mdm2 was
brought down with a mixture of monoclonal antibodies 4B2,
SMP14, 2A10, 2A9 and 4B11 [24]. One 10th of each immunoprecipi-
tate was analyzed by Western blotting, whereas the rest of the materi-
al was subjected to SDS^PAGE and autoradiography: gels were ¢xed
at room temperature for 30 min in a solution containing 25% MeOH^
7% acetic acid, treated with Amplify (Amersham Pharmacia,
NAMP100) at room temperature for 30 min, dried at 75‡C for 2 h,
and then exposed to Kodak BioMAX-MS ¢lm.
2.6. In vitro ubiquitination
Reactions were carried out in a total volume of 15 Wl, containing
bacterially expressed human E1, UbcH5, GST-Mdm2 (400 ng) and 10
Wg ubiquitin (Sigma), and 1 Wg/ml adenosine triphosphate (ATP)QS
(Boehringer), in ubiquitination bu¡er containing 40 mM Tris pH 7.5,
2 mM DTT, 5 mM MgCl2, and 25 ng/ml ubiquitin aldehyde (Ubal;
A⁄nity). p53 protein (1 Wl) produced in a wheat germ transcription-
coupled in vitro translation system (Promega) was added to the reac-
tion mixture. The reaction was allowed to proceed for 60 min at 30‡C,
then stopped by boiling for 5 min after addition of 15 Wl of 1.5U
protein sample bu¡er. p53 ubiquitination was analyzed by 8% SDS^
PAGE and Western blotting with a mixture of anti-p53 monoclonal
antibodies DO-1 and PAb1801. To monitor Mdm2 autoubiquitina-
tion, the membrane was reprobed with a rabbit polyclonal anti-Mdm2
antibody generated against a fusion protein between GST and resi-
dues 277^351 of human Mdm2.
2.7. In vivo ubiquitination
p53/mdm2 double null MEFs were plated at 0.75U106/10 cm dish,
and transfected 12 h later with various plasmid combinations, employ-
ing JetPEI. The total amount of DNA in each transfection was ad-
justed to 6 Wg/10 cm dish by addition of pCDNA3 empty vector
DNA. 20 h later, cells were treated with MG132 (25 WM) for 4 h,
harvested and lysed in 200 Wl of 1% SDS^TBS by boiling twice for
5 min after vigorous vortexing. Next, 400 Wl of TBS containing 1.5%
Triton X-100 was added to the lysate. After centrifugation for 10 min
at 15 000 rpm at room temperature, the supernatant was collected for
immunoprecipitation with a mixture of anti-p53 monoclonal antibod-
ies DO-1 and PAb1801, followed by Western blot analysis with anti-
HA antibody (Babco).
3. Results
3.1. Modulation of acetylation enhances the p53 response to
DNA damage and rescues p53 from Mdm2-mediated
degradation
To evaluate the overall contribution of acetylation to stabi-
lization of p53 after DNA damage, MEFs were pretreated for
4 h with the deacetylase inhibitor TSA prior to exposure to
ionizing radiation. As seen in Fig. 1A, pretreatment with TSA
caused a more robust and longer-lasting induction of p53.
Next, steady-state levels of p53 were examined in p53 null
H1299 cells, following transfection of p53 together with
Mdm2 or Mdm2 plus CBP. As expected, Mdm2 reduced
markedly the steady-state levels of p53 (Fig. 1B, lane 3). Im-
portantly, inclusion of CBP signi¢cantly attenuated this re-
duction (Fig. 1B, lane 4). p53 acetylation on CP-terminal ly-
sines can prevent p53 ubiquitination and degradation [25]. To
¢nd out whether this is the only mechanism whereby CBP
may protect p53 from Mdm2-mediated degradation, we
took advantage of the 4KR p53 mutant, in which lysines
372, 373, 381 and 382, the major sites for acetylation by
p300/CBP [4], were mutated to arginine. As shown in Fig.
1C (left panel), p53/4KR did not exhibit detectable C-terminal
acetylation by cotransfected CBP (lane 3), unlike wild-type
p53 whose acetylation was signi¢cantly enhanced by CBP
(lanes 1, 2). p53 remained susceptible to Mdm2-mediated deg-
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Fig. 1. Regulation of p53 by HAT activity. A: MEFs were pre-
treated with 100 nM TSA for 4 h or left untreated, and then ex-
posed to 1 Gy of Q-irradiation. Cell lysates were prepared at the in-
dicated time points after irradiation. MEFs treated with the
proteasome inhibitor MG132 (MG, 25 WM for 4 h) served as a pos-
itive control for p53 and Mdm2 stabilization. A mixture of the
monoclonal antibodies PAb421 and PAb248 was used for immuno-
blotting of mouse p53, and the 2A10 monoclonal antibody was
used for immunoblotting of Mdm2. Tubulin served as a loading
control. B: H1299 cells were transfected by the calcium phosphate
method with 0.5 Wg/6 cm dish of human p53 expression plasmid, ei-
ther alone or with 0.5 Wg of a plasmid encoding mouse Mdm2, or
with 0.5 Wg of mouse Mdm2 expression plasmid together with 5 Wg
of CBP expression plasmid. Western blot analysis for p53 was done
with a mixture of monoclonal antibodies PAb1801 and DO-1, and
for Mdm2 with monoclonal antibody 2A10. Transfected mouse
Mdm2 (Mdm2) and endogenous human Mdm2 (Hdm2) are indi-
cated. C: H1299 cells were transfected by the JetPEI procedure with
100 ng/6 cm dish (left panel) or 20 ng/6 cm dish (right panel) of the
indicated human p53 expression plasmid, either alone or with 40
ng/6 cm dish of human Mdm2 expression plasmid (right panel), to-
gether with 5 Wg/6 cm dish (left panel) or 2 Wg/6 cm dish (right pan-
el) of CBP-HA expression plasmid. The p53/4KR protein contains
lysine to arginine substitutions at positions 372, 373, 381 and 382 of
p53. In the right panel, green £uorescent protein (GFP) expression
plasmid was included as an internal transfection control. Western
blot analysis for acetylated p53 was done with a polyclonal anti-
pan-acetylated p53 [25] (left panel, Ac-p53). Total amount of p53
was monitored by reprobing the membrane with the polyclonal
anti-human p53 antibody CM1 (left panel, p53). In the right panel,
CBP-HA and p53 were detected with a monoclonal anti-HA anti-
body (CBP) or a mixture of PAb1801 and DO-1 (p53), respectively.
Numbers at the bottom represent relative p53 levels, after normal-
ization for GFP.
Fig. 2. Mdm2 acetylation in vitro. A: Recombinant fusion proteins
between GST and either full-length Mdm2 (Mdm2) or residues 2^
442 of Mdm2, lacking the RING ¢nger domain (Mdm2vR), were
incubated with recombinant catalytic fragment of CBP (CBP/cf,
lanes 1^3 and 5^7) or a catalytically inactive mutant version thereof
(lanes 4, 8), in the presence of [14C]acetyl-coenzyme A (CoA), as de-
scribed in Section 2. Reaction products were resolved by 10% SDS^
PAGE. Coomassie blue staining (right) of the gel indicates the input
protein bands. The autoradiogram shows the acetylation signals (left
panel), due to incorporation of radioactive acetyl groups. Mdm2-C
is a C-terminal fragment of Mdm2, comprising residues 356^482
fused to GST. Catalytically inactive CBP fragment was produced by
mutating leucine 1690 and cysteine 1691 into lysine and leucine, re-
spectively. Ac-CBP/cf indicates the position of autoacetylated CBP/
cf. B: In vitro Mdm2 acetylation with cell-derived full-length CBP
was carried out following immunoprecipitation of CBP-HA from
transfected HEK-293 cells. 10 10-cm dishes of HEK-293 cells, each
transfected with 15 Wg of HA-tagged CBP expression plasmid DNA,
were harvested 48 h post-transfection. Following immunoprecipita-
tion with anti-HA antibodies attached to protein A beads, the beads
were split in two equal parts and used for an in vitro acetylation as-
say of GST-free recombinant wild-type Mdm2 or Mdm2-4KR, as
indicated, in the presence of [14C]acetyl-CoA. M and C refer to
mock protein A beads and beads carrying immunoprecipitated CBP,
respectively. GST-free Mdm2 was prepared by cleavage with PreSci-
ssion protease (Section 2). Mdm2-4KR has lysines 466, 467, 469
and 470 replaced by arginines. Ac-Mdm2 and Ac-CBP indicate the
acetylated Mdm2 and autoacetylated CBP, respectively. C: An ex-
periment similar to the one in B was performed, except that p300-
HA was used instead of CBP-HA. M and p refer to mock protein
A beads and beads carrying immunoprecipitated p300, respectively.
D: Extracts of p53/mdm2 double null MEFs were subjected to im-
munoprecipitation of endogenous CBP with monoclonal antibody
C-1 (Santa Cruz). In vitro acetylation of GST-free recombinant
Mdm2 and subsequent analysis were carried out as in B.
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radation, even though the e¡ect of Mdm2 was apparently
attenuated, presumably owing to ablation of several lysine
residues critical for optimal p53 ubiquitination (Fig. 1C, right
panel, lanes 2, 3). Importantly, despite the absence of detect-
able acetylation on p53/4KR, the mutant protein was nicely
protected by CBP against Mdm2-mediated downregulation
(compare lanes 3, 4). This suggests that, besides direct acety-
lation of p53, CBP can also contribute to the p53 stabilization
by additional mechanism(s).
3.2. Mdm2 is acetylated in vitro in its RING ¢nger domain
To ¢nd out whether Mdm2 may be a direct target for in-
hibitory acetylation by CBP, we tested the acetyltransferase
activity of CBP towards Mdm2 in vitro. A bacterially ex-
pressed catalytic fragment of CBP acetylated recombinant
full-length human Mdm2 (Fig. 2A, lane 1), as well as a short
fragment of Mdm2 carrying the RING ¢nger domain (lane 2),
but not an Mdm2 mutant lacking the RING ¢nger (Mdm2-C;
lane 3). No acetylation of Mdm2-CT was obtained with a
catalytically inactive CBP fragment (lane 4). Thus, the
RING domain is the prime target for Mdm2 acetylation by
the catalytic fragment of CBP, consistent with a report that
the CP-terminal region of Mdm2 (residues 370^491), can be
acetylated by recombinant p300 HAT domain [26]. Indeed, we
could detect Mdm2 acetylation by a catalytically active frag-
ment of p300, albeit less e⁄cient than by CBP, whereas a
corresponding fragment P/CAF failed to acetylate Mdm2
while being very active towards p53 (data not shown). The
Mdm2 RING ¢nger encompasses a cluster of lysine residues
including lysines 466/467 and 469/470, which might be poten-
tial targets for acetylation. To address this possibility, GST
fusions with short Mdm2 RING ¢nger-derived peptides were
used as substrates for in vitro acetylation by CBP catalytic
fragment. Mutation of single individual lysine residues to ar-
ginine did not a¡ect acetylation; however, double mutations
at either K466/467 or 469/470 showed a signi¢cant reduction
in acetylation (data not shown).
The acetylation assay in Fig. 2A was performed with a
recombinant catalytic fragment of CBP. To ¢nd out whether
the full-length enzyme can also acetylate Mdm2, HA-tagged
CBP was immunoprecipitated from transfected HEK-293 cells
and assayed for acetylation of recombinant Mdm2 in vitro.
As shown in Fig. 2B, acetylation of wild-type Mdm2 by im-
munoprecipitated CBP was clearly detectable (lane 2, Ac-
Mdm2). Acetylation was markedly lower when Mdm2 carry-
ing lysine to arginine substitutions at positions 466, 467, 469
and 470 (Mdm2-4KR) was used as substrate (lane 4). Hence,
Mdm2 is targeted by an HAT activity associated with intact
cellular CBP, and e⁄cient acetylation in vitro requires lysine
residues located within the RING ¢nger cluster. HA-tagged
p300, immunoprecipitated from transfected HEK-293 cells,
also acetylated Mdm2 (Fig. 2C). However, while the amount
of immunoprecipitated p300 was much higher than that of
CBP (Fig. 2C, right panels, compare CBP-HA to p300-HA),
as was also the extent of its autoacetylation (left panels, com-
pare Ac-CBP to Ac-p300), Mdm2 acetylation was comparable
in both cases. Hence, p300 appears to be substantially less
potent than CBP as an Mdm2 HAT.
Endogenous CBP, immunoprecipitated from p53/Mdm2
double knockout MEFs, also promoted Mdm2 acetylation,
albeit less than the more abundant transfected CBP (Fig.
2D). Together, all these observations imply that CBP and to
Fig. 3. Mdm2 acetylation in vivo. A: HEK-293 cells were transfected with HA-Mdm2 or HA-Mdm2vRING (Mdm2vR), containing residues
1^436 of human Mdm2. 48 h later, cells were treated with 25 WM MG132 for 4 h, and labeled with [3H]acetate for 45 min at 37‡C. Cell lysates
were immunoprecipitated with a monoclonal anti-HA antibody (Babco). Right: Mdm2 immunoblot; left : autoradiography. Exposure: 60 days.
B: HEK-293 cells were transfected with CBP-HA together with HA-Mdm2 or HA-Mdm2-466/467R. 48 h later, cells were treated with 25 WM
MG132 for 4 h, and then with cycloheximide (50 Wg/ml) for 30 min at 37‡C and labeled with [3H]acetate for 90 min at 37‡C. Cells were lysed
in denaturing bu¡er (Section 2). Lysates were immunoprecipitated with a monoclonal anti-HA antibody (Babco). Amounts of CBP and Mdm2
in the immunoprecipitates, visualized by Western blot for HA and Coomassie staining, respectively, are shown above the gel autoradiography.
To calculate relative acetylation, the intensity of the scanned acetylated signal was divided by the intensity of the stained corresponding Mdm2
band. Exposure: 14 days. C: HEK-293 cells were transfected with HA-Mdm2 or HA-Mdm2-466/467R, with or without p300-HA. Analysis was
as in B. Ac-p300, autoacetylated p300.
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a lesser extent p300, but not P/CAF, acetylate Mdm2 prefer-
entially within the lysine cluster of the RING domain.
3.3. Mdm2 is acetylated in vivo
To assess Mdm2 acetylation in vivo, HEK-293 cells were
transfected with HA-tagged human Mdm2, either wild-type
(HA-Mdm2) or a deletion mutant lacking the RING domain
(HA-Mdm2vRING). Following treatment with the protea-
some inhibitor MG132 to block Mdm2 degradation, cells
were labeled brie£y with [3H]acetate. Mdm2 was precipitated
with anti-HA antibodies, followed by gel electrophoresis and
autoradiography. As seen in Fig. 3A, full-length Mdm2 was
appreciably acetylated under those conditions, whereas a mu-
tant lacking the RING ¢nger underwent only very minimal
labeling.
We next compared CBP-directed in vivo acetylation of
wild-type Mdm2 and an Mdm2 mutant carrying lysine to
arginine substitutions in two of the lysines located within
the RING ¢nger cluster. Cells were transfected with CBP-
HA together with either HA wild-type Mdm2 or HA-
Mdm2-466/467R. Incorporation of radioactive acetyl groups
was monitored essentially as in Fig. 3A. The relative extent of
acetylation was calculated as detailed in the legend to Fig. 3B;
it is of note that Mdm2 acetylation was practically undetect-
able under these conditions when a CBP expression plasmid
was not included in the transfection (data not shown). Muta-
tion of lysines 466 and 467 reduced by about two-fold the
relative extent of acetylation of Mdm2 (Fig. 3B, compare
lanes 3 and 1). Thus, these residues appear to be major sites
for CBP-directed acetylation of Mdm2 also in living cells.
In contrast to CBP, cotransfection with p300-HA did not
enhance acetylation of Mdm2 in vivo (Fig. 3C), although the
transfected p300 underwent substantial autoacetylation (Fig.
3C, Ac-p300). Thus, CBP is remarkably more e¡ective than
p300 in promoting Mdm2 acetylation in vivo.
3.4. Mutations mimicking Mdm2 acetylation impair p53
ubiquitination and degradation
The RING ¢nger of Mdm2 is crucial for its E3 ubiquitin
ligase activity. Given that Mdm2 acetylation occurs primarily
within the RING ¢nger domain, it was conceivable that
Mdm2 acetylation might hamper its E3 ligase activity. To
assess the impact of acetylation on Mdm2 activity, lysines
466 and 467 of Mdm2 were mutated to glutamine to mimic
constitutive acetylation. In a cell-free assay for E3 ligase ac-
tivity, wild-type Mdm2 promoted the polyubiquitination of
p53 in a dose-dependent manner (Fig. 4A, upper panel, lanes
3^5, polyub-p53). Under the same conditions, the 466/467Q
acetylation mimic mutant displayed a reduced ability to drive
p53 polyubiquitination, particularly at relatively high Mdm2
concentrations (compare lanes 7, 8 to lanes 4, 5); in contrast,
p53 monoubiquitination was not a¡ected by the mutations.
Interestingly, Mdm2-466/467Q also exhibited a partial defect
in autoubiquitination (Fig. 4A, bottom panel ; compare lanes
Fig. 4. Mutants mimicking Mdm2 acetylation possess reduced E3 activity and are de¢cient in p53 degradation. A: In vitro p53 ubiquitination
was carried out as described in Section 2, in the presence of increasing amounts of GST-Mdm2 or GST-Mdm2-466/467Q. p53 was visualized
by immunoblotting with a mixture of the p53-speci¢c monoclonal antibodies DO-1 and PAb1801 (upper panel). polyub-p53, polyubiquitinated
p53. Mdm2 autoubiquitination was examined by reprobing the same membrane with a polyclonal anti-Mdm2 antibody (bottom panel).
Amounts of GST-Mdm2 and GST-Mdm2-466/467Q were monitored by Western blot analysis with a mixture of the Mdm2-speci¢c monoclonal
antibodies 4B11 and 2A9, following the loading of 1/60 of the reaction contents on an SDS^PAGE gel (middle panel). B: p53/mdm2 double
null MEFs were transiently transfected with expression plasmids for human p53 and HA-ubiquitin, together with wild-type Mdm2 or Mdm2-
K466/467Q (466/467Q). A GFP expression plasmid was also included. 24 h later, p53 immunoprecipitation was performed with a mixture of
DO-1 and PAb1801. Covalent conjugates of p53 with HA-tagged ubiquitin (ub-p53) were visualized with an anti-HA antibody (upper panel).
Transfection e⁄ciency was monitored by analysis of cotransfected GFP. p53 and Mdm2 were monitored with a mixture of DO-1 and PAb1801
and a mixture of 2A9 and 4B11, respectively. C: p53/mdm2 double null MEFs were transiently transfected with a ¢xed amount of p53 expres-
sion plasmid (50 ng/6 cm dish) and increasing amounts (0.5 and 1 Wg, respectively) of HA-Mdm2 or HA-Mdm2K466/467Q expression plasmids,
together with a GFP expression plasmid. p53 and Mdm2 were monitored as in B.
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6^8 to lanes 3^5). Hence, mutations that mimic the acetylated
state of Mdm2 partially compromise its E3 activity.
To investigate whether Mdm2 acetylation a¡ects its ability
to ubiquitinate p53 in vivo, p53/mdm2 double null MEFs
were transfected with p53 in combination with either wild-
type or mutant Mdm2. While wild-type Mdm2 promoted e⁄-
cient p53 ubiquitination (Fig. 4B, upper panel, lanes 3, 5), the
466/467Q mutant was severely compromised (lanes 4, 6). In
fact, the disabling e¡ect of the mutations on p53 ubiquitina-
tion was much more pronounced in vivo than in vitro, sug-
gesting that Mdm2 acetylation may a¡ect the interaction of
Mdm2 with additional proteins, absent from the cell-free sys-
tem, which modulate p53 polyubiquitination within cells.
To determine whether the reduced ubiquitination of p53
compromises its degradation, p53 levels were monitored in
p53/mdm2 double null MEFs transfected with a ¢xed amount
of p53 expression plasmid, together with increasing amounts
of a plasmid encoding either wild-type Mdm2 (Fig. 4C, lanes
2, 3) or the 466/467Q mutant (lanes 4, 5). Whereas wild-type
Mdm2 decreased markedly the steady-state levels of p53 (Fig.
4C, compare lanes 2, 3 to lane 1), comparable levels of
Mdm2-466/467Q were relatively ine⁄cient in downregulating
p53 (lanes 4, 5). Thus, Mdm2 mutations that mimic acetyla-
tion within the RING ¢nger domain severely reduce the E3
activity of Mdm2, as well as its ability to promote p53 deg-
radation.
4. Discussion
We report that Mdm2 can be acetylated in vitro and in
vivo. Several HATs, including p300, CBP and P/CAF, can
e⁄ciently acetylate p53 [21,27,28]. Of those, we show that
CBP is the most e⁄cient mediator of Mdm2 acetylation and
p300 is substantially less e⁄cient, whereas P/CAF does not
target Mdm2 at all, although it binds Mdm2 [29]. Mdm2
binds both CBP and p300. Furthermore, in vitro acetylation
of Mdm2 by recombinant HATs or HAT fragments has also
been reported [21,26], although others have challenged the
relevance of those ¢ndings [30]. We ¢nd that acetylation oc-
curs mainly within the RING ¢nger domain of Mdm2. Yuan
and coworkers reported that, in addition to a C-terminal frag-
ment (370^491), p300-dependent in vitro acetylation can also
occur within a central fragment (amino acids 124^246) of
Mdm2 [26] ; this may account for the residual CBP and
p300-dependent acetylation signal observed with the Mdm2/
4KR mutant. Of note, a recent study did not observe acety-
lation of Mdm2 by p300, neither in vitro nor in vivo [30].
Since p300 is a less potent HAT for Mdm2 than CBP, the
extent of Mdm2 acetylation by p300 may have been below
detection in the study of Zeng et al.
Mdm2 acetylation was mapped in part to lysines 466/467,
which reside within the proposed nucleolar localization signal
(NoLS) of the protein [31]. It was thus tempting to speculate
that Mdm2 acetylation, through changing the charge of this
basic NoLS, might serve to modulate the intracellular local-
ization of the protein. However, Mdm2-466/467Q was trans-
located into the nucleolus as e⁄ciently as wild-type Mdm2,
when assayed in the presence of p14ARF (data not shown). On
the other hand, Mdm2-466/467Q displayed a pronounced de-
fect in p53 ubiquitination and degradation, as well as in au-
toubiquitination in vitro. This suggests that Mdm2 acetyl-
ation, when occurring in vivo, is likely to serve as an
additional mechanism for inactivation of Mdm2 and thus
more e⁄cient induction of a p53 response.
p53 acetylation is generally regarded as an important com-
ponent in p53 activation by various types of stress. Our data
raise the possibility that Mdm2 acetylation may potentially
play a similar role. Thus, regulated protein acetylation may
contribute to the p53 response through a dual mechanism,
involving simultaneous activation of p53 and inactivation of
its negative regulator Mdm2.
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